ANI Pharmaceuticals, Inc. (ANIP) return on equity (ROE)

Return on equity · fiscal 2025
14.5%

ANI Pharmaceuticals, Inc. (ANIP) earned a return on equity of 14.5% in fiscal 2025 (the year ended December 31, 2025). That is 18.8 percentage points higher than the -4.3% of fiscal 2024. Figures as of 17 Nov 2026, 20:45 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
14.5%
Change on fiscal 2024
+18.8 pts
Highest on record
20.6%fiscal 2014
Lowest on record
-14.1%fiscal 2022
Fiscal years on record
132013–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

ANI Pharmaceuticals, Inc. return on equity (ROE), in more detail

Across the 13 fiscal years on record (2013–2025), the highest was 20.6% in fiscal 2014 and the lowest -14.1% in fiscal 2022. The fiscal 2025 figure is higher than in 92% of the 12 earlier fiscal years on record, whose median is 1.5%.

History · 13 fiscal years

Return on equity by fiscal year

ANI Pharmaceuticals, Inc. return on equity (ROE), year by year

ANI Pharmaceuticals, Inc. (ANIP) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202514.5% 18.8 pts up
2024-4.3% 8.4 pts down
20234.1% 18.3 pts up
2022-14.1% 1.4 pts down
2021-12.8% 1.2 pts down
2020-11.5% 14.4 pts down
20192.9% 5.0 pts down
20187.9% 8.5 pts up
2017-0.6% 2.9 pts down
20162.3% 7.3 pts down
20159.6% 11.0 pts down
201420.6% 19.8 pts up
20130.7%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on ANIP

ANI Pharmaceuticals, Inc., figure by figure

ANI Pharmaceuticals, Inc. (ANIP) overview: price, valuation and scorecard

ANI Pharmaceuticals, Inc. return on equity (ROE): questions and answers

What is ANI Pharmaceuticals, Inc.'s return on equity?

ANI Pharmaceuticals, Inc. (ANIP) earned a return on equity of 14.5% in fiscal 2025 (the year ended December 31, 2025). That is 18.8 percentage points higher than the -4.3% of fiscal 2024.

Is ANI Pharmaceuticals, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 92% of the 12 earlier fiscal years on record, whose median is 1.5%.

What are the highest and lowest return on equity figures on record for ANI Pharmaceuticals, Inc.?

Across the 13 fiscal years on record (2013–2025), the highest was 20.6% in fiscal 2014 and the lowest -14.1% in fiscal 2022.

How is ANI Pharmaceuticals, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “ANI Pharmaceuticals, Inc. (ANIP) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/ANIP/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.